Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

HealthDay News — The US Department of Health and Human Services has announced a major initiative to reform the organ transplant system. This action follows an investigation by the Health Resources and ...

HealthDay News — Small-group professional coaching can reduce physician burnout rates by up to nearly 30%, according to a study published online July 11 in the Journal of General Internal Medicine.

Six or 9 months of bedaquiline, delamanid, linezolid, and clofazimine was not noninferior to longer standard of care.